SPRAVATO® Therapy

A prescription, FDA-approved nasal spray used to treat depression and suicidal ideation

PAM Voyages of Conroe and PAM Voyages of Sugar Land are now able to provide appropriate adult patients with SPRAVATO®. SPRAVATO®, the only FDA-approved nasal spray for adults with treatment-resistant depression (TRD), reduces depression symptoms when two or more oral antidepressants haven’t worked. SPRAVATO® can be taken with or without an oral antidepressant. It’s the first and only FDA-approved treatment for depression that targets the glutamate system.

Start Your Recovery

Scroll To Explore

structured, supervised care

Getting Started

Potential Patients

You can schedule a SPRAVATO® consultation directly with us to see if treatment could be an option for you. You can also work with your current doctor to see if SPRAVATO® may be right for you and complete our patient intake form to get started. Our medical staff and care team are committed to partnering with you and your doctor to support you during your treatment journey with SPRAVATO®. During the SPRAVATO® consultation, a healthcare provider will review your medical history, treatment goals, and insurance to determine if SPRAVATO® is right for you. Treatment is not usually administered on this first visit. Our doctors and nurses proactively coordinate care and will ensure an open line of communication with your referring doctor to monitor your progress. In addition, our care team will guide you through your journey, clearly explaining what to expect during SPRAVATO® treatment sessions. They will also work with your insurance provider to confirm your coverage and your costs prior to your treatment with SPRAVATO®.

Making Each Day Count

What You Can Expect

We monitor your treatment closely and keep an open line of communication with your referring physician.

Before Treatment

See the section above. You will have met with our team previously to have had a consultation and full medical review.

Day of Treatment

On treatment days, you will administer SPRAVATO® nasal spray yourself under the supervision of a healthcare provider at the treatment center, followed by a 2-hour monitoring period. Our doctors and nurses will also watch for any changes in respiratory status (including pulse oximetry) and blood pressure.

After Treatment

Please keep in mind that you should not drive or operate machinery until the next day after a night of restful sleep. For the first month, you’ll take SPRAVATO® twice per week, then once per week for the second month. After that, you and your
provider will have the flexibility to decide your treatment frequency. You will not be able to self-administer SPRAVATO® at home.

Important Safety Information

What to Know about SPRAVATO®

These include sleepiness (sedation); fainting; dizziness; spinning sensation; anxiety; or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation); breathing problems (respiratory depression and respiratory arrest); abuse and misuse; and increased risk of suicidal thoughts and actions. Because of the risks for sedation, dissociation, respiratory depression, and abuse and misuse, SPRAVATO® is only available through a restricted distribution program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program.

SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.